MIF and cancer: identified a number of cancer‐specific epitopes including a peptide derived from macrophage migration inhibitory factor (MIF),9 for which a TCRm antibody was subsequently developed that was shown to reduce tumor burden both in vitro and in vivo.10 Although such cell line studies have generated a significant amount of information,11 primary tissues are generally more desirable as they have not gone through the extended culture and propagation under artificial conditions which inevitably affects the composition of the peptidomes.